U.S., U.K. volume bets on AZD1222 come into question with vaccine efficacy data 

As the U.K. moves to review AZD1222 from AstraZeneca and Oxford, efficacy data from the three front-runner COVID-19 vaccines provides an opportunity to take stock of governments’ bets on which candidates warranted the most investment, and of how the landscape could shift if AZ opts for a second trial.

Both the U.S. and U.K. made AZD1222 their biggest investments by volume, largely due to its lower price. But as emerging data raises questions about its relative efficacy and optimal dosing regimen, the adenoviral vector vaccine could see its role in the COVID-19 response dwindling, with the possibility that it may never become available stateside...